Xlife Sciences

Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle - Seite 2

Information for investors: Xlife Sciences AG, Dennis Lennartz, [e-mail]

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone [phone]
[e-mail], www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS) 

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch 

Disclaimer 

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. 

---

End of Media Release

---

Language:	English
Company:	Xlife Sciences AG
	Talacker 35
	8001 Zürich
	Switzerland
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.xlifesciences.ch
ISIN:	CH0461929603
Valor:	A2PK6Z
Listed:	SIX Swiss Exchange
EQS News ID:	1539641